Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics. The company's core product, ST266, is a biologic with unique and powerful healing potential, currently being tested in Phase I clinical trials for COVID-19 and various ophthalmic indications. Noveome operates in the biopharmaceutical market, targeting healthcare providers and patients in need of advanced treatments for serious conditions. The business model revolves around research and development, clinical trials, and eventual commercialization of their biologic products. Revenue is generated through partnerships, grants, and future sales of approved treatments. Noveome's innovative Cribriform Targeted Device (CT6) enhances drug delivery to the nasal cavity, ensuring high absorption and efficacy. The company is headquartered in Pittsburgh, PA, and is driven by a passionate team dedicated to making a positive impact on lives.

Keywords: biopharmaceutical, biologics, ST266, COVID-19, ophthalmic, clinical trials, drug delivery, healthcare, innovation, Pittsburgh